Novel Coronavirus Pneumonia (COVID-19)
Conditions
Interventions
control group:Do not give Lianhua Qingwen
Lianhua Qingwen Group:Lianhua Qingwen Capsules 4 capsules/time or Lianhua Qingwen Granules 1 bag/time, 3 times a day
Sponsors
Ruijin Hospital, Shanghai Jiaotong University School of Medicine
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Asymptomatic infections and mild confirmed cases of the new coronavirus found in the "New Coronary Virus Pneumonia Diagnosis and Treatment Program (Trial Version 9)" by etiological testing; 2. The ward/class can accept the entire group size and can be selected according to the actual situation, and standardized and homogeneous diagnosis and treatment shall be carried out in accordance with the "New Coronavirus Pneumonia Diagnosis and Treatment Plan (Trial Version 9)". 3. The patient is over 18 years old (including 18 years old), male or female; 4. Patients voluntarily signed a written informed consent before the start of the study.
Exclusion criteria
Exclusion criteria: 1. Ordinary, severe and critical patients with novel coronavirus pneumonia confirmed by etiological testing and clinical manifestations or signs; 2. Groups of patients who cannot accept standardized and homogeneous diagnosis and treatment by medical teams; 3. The patient group is small and not suitable for participating in the cluster random observation group; 4. According to the judgment of the investigator, patients with severe diseases such as malignant diseases, autoimmune diseases, liver and kidney diseases, blood diseases, nervous system diseases, and endocrine system diseases may affect the patient's participation in the trial or the outcome of the study; 5. Pregnant or breastfeeding women; 6. Patients who have participated in other clinical studies within the past 3 months; 7. Allergic constitution, such as those with a history of allergies to two or more drugs or food, or those who are known to be allergic to the ingredients of this medicine; 8. The investigator believes that there are any factors that are unsuitable for enrollment or that affect the efficacy evaluation of subjects.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The total negative rate of nucleic acid test within 7 days after staying in the cabin;; | — |
Countries
China
Contacts
Public ContactNing Guang
Ruijin Hospital, Shanghai Jiaotong University School of Medicine
Outcome results
None listed